A Phase 1 interventional study of NKF-INS(G) and US-Lantus® in Healthy Participants, sponsored by Xentria, Inc.. Completed at 1 site in South Africa. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Xentria, Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
A single center, single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS(G), US-Lantus®, and EU-Lantus® using the euglycemic clamp technique in healthy male adult volunteers
Xentria, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single subcutaneous dose administered over three treatment periods
Drug: US-Lantus®
Single subcutaneous dose administered over three treatment periods
Drug: EU-Lantus®
Single subcutaneous dose administered over three treatment periods
Drug: NKF-INS(G)
Single subcutaneous dose of 0.5 IU/kg administered over three periods
Single subcutaneous dose of 0.5 IU/kg administered over three periods
Single subcutaneous dose of 0.5 IU/kg administered over three periods
Area Under the M1 Concentration-Time Curve From 0 to 12 Hours (AUC0-12h of M1)
Compared the pharmacokinetics (PK) of NKF-INS Glargine(G) to United States (US)-approved and European Union (EU)-authorized Lantus to demonstrate PK similarity for metabolite 21A-Gly-human insulin (M1)
Time frame: 0 to 12 hours post-dose
Maximum Capacity (Cmax) of M1
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 24 hours post-dose
Area Under the Concentration-Time Curve AUC0-6h, AUC6-12h and AUC0-12h of M1
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 12 hours post-dose
Area Under the Concentration-Time Curve AUC12-18h and AUC12-24h of M1
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 12 to 24 hours post-dose
Area Under the Concentration-Time Curve AUC18-24h of M1
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 18 to 24 hours post-dose
Time to Maximum Concentration (Tmax) of M1
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 24 hours post-dose
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M1
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 24 hours post-dose
Maximum Concentration (Cmax) of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 24 hours post-dose
Area Under the Concentration-Time Curve AUC0-12h and AUC0-24h of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 24 hours post-dose
Area Under the Concentration-Time Curve AUC0-6hr of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 6 hours post-dose
Area Under the Concentration-Time Curve AUC6-12h of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 6 to 12 hours post-dose
Area Under the Concentration-Time Curve AUC12-18h of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 12 to 18 hours post-dose
Area Under the Concentration-Time Curve AUC18-24h of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 18 to 24 hours post-dose
Area Under the Concentration-Time Curve AUC12-24h of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 12 to 24 hours post-dose
Time to Maximum Concentration (Tmax) of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 24 hours post-dose
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Insulin Glargine
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
Time frame: 0 to 24 hours post-dose
GIRAUC0-24h, GIRAUC0-end of Clamp up to 24hours, GIRAUC0-6h, GIRAUC0-12h
Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
Time frame: 0 to 24 hours post-dose
GIRAUC0-∞
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
Time frame: 0 to 24 hours post-dose
GIRAUC6-12h
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
Time frame: 6 to 12 hours post-dose
GIRAUC12-18h and GIRAUC12-24h
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
Time frame: 12 to 24 hours post-dose
GIRAUC18-24h
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
Time frame: 18 to 24 hours post-dose
GIRmax
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.
Time frame: 0 to 24 hours post-dose
Time to GIRmax
Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.
Time frame: 0 to 24 hours post-dose
Total Amount of Glucose Infused During Clamp Procedure (Gtot)
Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.
Time frame: 0 to 24 hours post-dose
| Milestone | NKF-INS(G), EU-Lantus, US-Lantus | NKF-INS(G), US-Lantus, EU-Lantus | EU-Lantus, NKF-INS(G), US-Lantus | EU-Lantus, US-Lantus, NKF-INS(G) | US-Lantus, NKF-INS(G), EU-Lantus | US-Lantus, EU-Lantus, NKF-INS(G) |
|---|---|---|---|---|---|---|
| Started | 19 | 19 | 19 | 19 | 19 | 19 |
| Completed | 18 | 18 | 19 | 19 | 18 | 19 |
| Not completed | 1 | 1 | 0 | 0 | 1 | 0 |
Compared the pharmacokinetics (PK) of NKF-INS Glargine(G) to United States (US)-approved and European Union (EU)-authorized Lantus to demonstrate PK similarity for metabolite 21A-Gly-human insulin (M1)
| hours*ng/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the M1 Concentration-Time Curve From 0 to 12 Hours (AUC0-12h of M1) | 7.970 ± 32.479 | 7.781 ± 33.428 | 7.564 ± 33.488 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| ng/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Maximum Capacity (Cmax) of M1 | .455 ± 30.623 | .450 ± 33.288 | .433 ± 31.454 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*ng/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| AUC0-6h of M1 | 1.715 ± 32.342 | 1.568 ± 38.612 | 1.584 ± 32.554 |
| AUC6-12h of M1 | 1.782 ± 41.523 | 1.767 ± 42.431 | 1.723 ± 37.567 |
| AUC0-12h of M1 | 4.082 ± 32.480 | 3.875 ± 36.702 | 3.845 ± 32.363 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*ng/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| AUC12-18h of M1 | 1.675 ± 28.559 | 1.582 ± 41.939 | 1.571 ± 33.503 |
| AUC12-24h of M1 | 3.322 ± 27.449 | 3.165 ± 43.001 | 3.222 ± 30.522 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*ng/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the Concentration-Time Curve AUC18-24h of M1 | 1.105 ± 51.367 | 1.101 ± 43.570 | 1.148 ± 35.329 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of M1 | 9.867 ± 47.511 | 10.823 ± 39.093 | 9.537 ± 58.511 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*ng/ml | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M1 | 12.250 ± 19.317 | 13.567 ± 18.414 | 12.352 ± 22.818 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| pg/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Maximum Concentration (Cmax) of Insulin Glargine | 193.763 ± 38.721 | 188.896 ± 38.449 | 186.117 ± 31.301 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*pg/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| AUC0-12h of insulin glargine | 836.127 ± 163.281 | 793.846 ± 183.945 | 791.192 ± 136.684 |
| AUC0-24h of insulin glargine | 1115.563 ± 192.353 | 1169.504 ± 171.260 | 1062.236 ± 156.306 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*pg/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the Concentration-Time Curve AUC0-6hr of Insulin Glargine | 512.697 ± 116.596 | 457.218 ± 128.758 | 458.443 ± 102.241 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*pg/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the Concentration-Time Curve AUC6-12h of Insulin Glargine | 536.777 ± 51.377 | 549.668 ± 49.277 | 506.895 ± 53.693 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*pg/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the Concentration-Time Curve AUC12-18h of Insulin Glargine | 287.389 ± 127.986 | 302.907 ± 69.204 | 326.417 ± 69.138 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*pg/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the Concentration-Time Curve AUC18-24h of Insulin Glargine | 319.948 ± 79.932 | 215.605 ± 98.843 | 226.813 ± 164.522 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*pg/mL | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the Concentration-Time Curve AUC12-24h of Insulin Glargine | 374.189 ± 158.113 | 387.468 ± 99.751 | 450.063 ± 96.891 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of Insulin Glargine | 1.545 ± 157.986 | 1.907 ± 170.486 | 1.534 ± 157.958 |
Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.
| hours*ng/ml | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Insulin Glargine | 5440.993 ± 58.960 | 5987.074 ± 59.127 | 5673.057 ± 80.945 |
Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
| min*mg/min | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| GIRAUC0-24h | 198256.821 ± 47.267 | 200966.263 ± 41.906 | 187594.648 ± 46.027 |
| GIRAUC0-end of clamp up to 24h | 198256.821 ± 47.267 | 200966.263 ± 41.906 | 187594.648 ± 46.027 |
| GIRAUC0-6h | 33586.896 ± 52.470 | 32444.949 ± 46.868 | 32294.837 ± 38.298 |
| GIRAUC0-12h | 103441.058 ± 42.081 | 102868.998 ± 38.482 | 98785.375 ± 35.280 |
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
| min*mg/min | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| GIRAUC0-∞ | 201674.663 ± 57.803 | 208064.846 ± 55.531 | 197857.889 ± 57.928 |
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
| min*mg/min | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| GIRAUC6-12h | 67272.256 ± 45.091 | 68561.314 ± 37.827 | 65410.503 ± 36.943 |
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
| min*mg/min | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| GIRAUC12-18h | 58633.790 ± 42.093 | 57219.839 ± 60.368 | 55497.942 ± 52.951 |
| GIRAUC12-24h | 95634.920 ± 46.929 | 92197.484 ± 71.178 | 89431.857 ± 60.379 |
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies
| min*mg/min | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| GIRAUC18-24h | 34730.926 ± 79.974 | 34497.876 ± 83.647 | 32877.898 ± 72.987 |
Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.
| mg/min | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| GIRmax | 242.738 ± 39.069 | 239.782 ± 35.090 | 232.469 ± 35.694 |
Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.
| min | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Time to GIRmax | 563.411 ± 36.457 | 600.146 ± 30.112 | 530.081 ± 43.786 |
Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.
| mg/kg | US-Lantus® | NKF-INS(G) | EU-Lantus® |
|---|---|---|---|
| Total Amount of Glucose Infused During Clamp Procedure (Gtot) | 198256.821 ± 47.267 | 200966.263 ± 41.906 | 187594.648 ± 46.027 |
Collected over Day 1 to EOS visit (2-11 days after last administration of study drug), up to 7 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| United States (US)-Lantus® | 0/113 (0%) | 0/113 (0%) | 20/113 (17.7%) |
| NKF-INS Glargine (G) | 0/114 (0%) | 0/114 (0%) | 20/114 (17.5%) |
| European Union (EU)-Lantus® | 0/111 (0%) | 0/111 (0%) | 31/111 (27.9%) |
| Event | United States (US)-Lantus® | NKF-INS Glargine (G) | European Union (EU)-Lantus® |
|---|---|---|---|
| HeadacheNervous system disorders | 7/113 | 9/114 | 6/111 |
| Infusion site swellingGeneral disorders | 1/113 | 6/114 | 5/111 |
| Injection site painGeneral disorders | 5/113 | 1/114 | 5/111 |
| DizzinessNervous system disorders | 2/113 | 1/114 | 3/111 |
| InfluenzaInfections and infestations | 0/113 | 0/114 | 3/111 |
| Infusion site painGeneral disorders | 1/113 | 0/114 | 2/111 |
| DiarrhoeaGastrointestinal disorders | 0/113 | 1/114 | 2/111 |
| Soft tissue injuryInjury, poisoning and procedural complications | 0/113 | 0/114 | 2/111 |
| Blood creatine phosphokinase increasedInvestigations | 2/113 | 0/114 | 0/111 |
| Injection site pruritusGeneral disorders | 1/113 | 2/114 | 0/111 |
| Age, Customized(years) | NKF-INS(G), EU-Lantus, US-Lantus | NKF-INS(G), US-Lantus, EU-Lantus | EU-Lantus, NKF-INS(G), US-Lantus | EU-Lantus, US-Lantus, NKF-INS(G) | US-Lantus, NKF-INS(G), EU-Lantus | US-Lantus, EU-Lantus, NKF-INS(G) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 32.16 ± 8.55 | 31.53 ± 6.75 | 31.16 ± 7.81 | 34.21 ± 7.02 | 32.79 ± 8.48 | 29.74 ± 5.76 | 31.93 ± 7.43 |
| Sex/Gender, Customized(Participants) | NKF-INS(G), EU-Lantus, US-Lantus | NKF-INS(G), US-Lantus, EU-Lantus | EU-Lantus, NKF-INS(G), US-Lantus | EU-Lantus, US-Lantus, NKF-INS(G) | US-Lantus, NKF-INS(G), EU-Lantus | US-Lantus, EU-Lantus, NKF-INS(G) | Total |
|---|---|---|---|---|---|---|---|
| Male | 19 | 19 | 19 | 19 | 19 | 19 | 114 |
| Race/Ethnicity, Customized(participants) | NKF-INS(G), EU-Lantus, US-Lantus | NKF-INS(G), US-Lantus, EU-Lantus | EU-Lantus, NKF-INS(G), US-Lantus | EU-Lantus, US-Lantus, NKF-INS(G) | US-Lantus, NKF-INS(G), EU-Lantus | US-Lantus, EU-Lantus, NKF-INS(G) | Total |
|---|---|---|---|---|---|---|---|
| Black or African American | 15 | 18 | 16 | 15 | 15 | 18 | 97 |
| Other | 1 | 1 | 2 | 1 | 2 | 0 | 7 |
| White | 3 | 0 | 1 | 3 | 2 | 1 | 10 |
| BMI(kg/m^2) | NKF-INS(G), EU-Lantus, US-Lantus | NKF-INS(G), US-Lantus, EU-Lantus | EU-Lantus, NKF-INS(G), US-Lantus | EU-Lantus, US-Lantus, NKF-INS(G) | US-Lantus, NKF-INS(G), EU-Lantus | US-Lantus, EU-Lantus, NKF-INS(G) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 23.87 ± 2.61 | 24.48 ± 2.68 | 23.76 ± 2.65 | 25.03 ± 2.59 | 24.57 ± 2.17 | 25.9 ± 2.31 | 24.6 ± 2.56 |
| Height (cm)(cm) | NKF-INS(G), EU-Lantus, US-Lantus | NKF-INS(G), US-Lantus, EU-Lantus | EU-Lantus, NKF-INS(G), US-Lantus | EU-Lantus, US-Lantus, NKF-INS(G) | US-Lantus, NKF-INS(G), EU-Lantus | US-Lantus, EU-Lantus, NKF-INS(G) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 175.08 ± 6.64 | 171.94 ± 5.91 | 172.72 ± 6.33 | 173.69 ± 7.01 | 171.85 ± 6.03 | 169.81 ± 6.42 | 172.51 ± 6.47 |
| Weight(kg) | NKF-INS(G), EU-Lantus, US-Lantus | NKF-INS(G), US-Lantus, EU-Lantus | EU-Lantus, NKF-INS(G), US-Lantus | EU-Lantus, US-Lantus, NKF-INS(G) | US-Lantus, NKF-INS(G), EU-Lantus | US-Lantus, EU-Lantus, NKF-INS(G) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 73.16 ± 9.18 | 72.48 ± 9.48 | 70.94 ± 9.29 | 75.4 ± 8.07 | 72.59 ± 7.44 | 74.96 ± 10.32 | 73.25 ± 8.94 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2024 to primary completion in Jul 2025, 8 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xentria, Inc.